文献速递咽喉与嗓音

纳米颗粒递送RNA疗法改变声带组织对损伤的反应

Nanoparticle delivery of RNA-based therapeutics to alter the vocal fold tissue response to injury.
PubMed 文献 · Laryngoscope · 2017-12-14

该研究通过体外实验和兔声带损伤模型,评估了新型合成寡聚物lipitoid复合siRNA递送Smad3的可行性。体外显示lipitoid无额外毒性,20分钟孵育于1×PBS中可达最大Smad3敲低;结论首次证实声带靶向基因操控及lipitoid局部递送核酸的潜力。

要点

  • lipitoid复合siRNA在体外无额外细胞毒性
  • 20分钟1×PBS孵育实现最大Smad3敲低
  • 兔声带损伤模型中注射后4和24小时Smad3表达显著降低

核心结论

  • 首次证实声带靶向基因操控及lipitoid局部递送遗传物质在体内的潜力。

研究设计与样本

  • 体外研究:永生化人声带成纤维细胞和原代兔声带成纤维细胞。
  • 体内研究:兔声带损伤模型,局部注射lipitoid复合siRNA。

主要发现

  • 体外lipitoid与商用试剂相比未增加细胞毒性。
  • 体外20分钟孵育于1×PBS中实现最大Smad3敲低。

临床怎么用

  • lipitoid可作为声带局部递送siRNA的潜在载体,用于调控损伤后纤维化相关基因表达。

局限性

  • 证据级别为NA,研究为临床前体外和动物实验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: Our laboratory and others hypothesized that Smad3 is a principle mediator of the fibrotic phenotype in the vocal folds (VFs), and we further posited that alteration of Smad3 expression through short interfering (si)RNA holds therapeutic promise, yet delivery remains challenging. To address this issue, we employed a novel synthetic oligomer, lipitoid, complexed with siRNA to improve stability and cellular uptake with the goal of increased efficiency of RNA-based therapeutics. STUDY DESIGN: In vitro study and in vivo animal model. METHODS: In vitro, lipitoid cytotoxicity was quantified via colorimetric and LIVE/DEAD assays in immortalized human VF fibroblasts and primary rabbit VF fibroblasts. In addition, optimal incubation interval and solution for binding siRNA to lipitoid for intracellular delivery were determined. In vivo, a rabbit model of VF injury was employed to evaluate Smad3 knockdown following locally injected lipitoid-complexed siRNA. RESULTS: In vitro, lipitoid did not confer additional toxicity compared to commercially available reagents. In addition, 20-minute incubation in 1× phosphate-buffered saline resulted in maximal Smad3 knockdown. In vivo, Smad3 expression increased following VF injury. This response was significantly reduced in injured VFs at 4 and 24 hours following injection (P = .035 and .034, respectively). CONCLUSIONS: The current study is the first to demonstrate targeted gene manipulation in the VFs as well as the potential utility of lipitoid for localized delivery of genetic material in vivo. Ideally, these data will serve as a platform for future investigation regarding the functional implications of therapeutic gene manipulation in the VFs. LEVEL OF EVIDENCE: NA. Laryngoscope, 128:E178-E183, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Hiwatashi N, Kraja I, Benedict PA, et al. Nanoparticle delivery of RNA-based therapeutics to alter the vocal fold tissue response to injury. Laryngoscope. 2017. PMID: 29238989. doi:10.1002/lary.27047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。